CervoMed Inc. Common Stock (CRVO)

About CRVO

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

15

Website

www.cervomed.com

Fundamentals

1-day range

$2.68$2.99

Market cap

$37.33M

P/E (trailing)

—

P/E (forward)

-1.82

EPS (trailing)

$-3.21

Dividend yield

—

Beta

-4.31

Avg. volume

5.69M

Dividend pay date

December 14, 2018

Forecasts

5 analyst ratings

CervoMed Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• CRVO

  CervoMed Inc. Common Stock

  $2.6

  ▼ 1.52%
  Market cap $37.33MP/E —
  $2.13$11.25
• APLM

  Apollomics Inc. Class A Ordinary Shares

  $26.6

  ▲ 1.14%
  Market cap $37.33MP/E —
  $3.66$42.12
• IXHL

  Incannex Healthcare Inc. Common Stock

  $3.61

  ▼ 2.17%
  Market cap $37.21MP/E —
  $2.49$20.64
• NNVC

  NanoViricides Inc. Common Stock

  $1.24

  ▼ 3.12%
  Market cap $35.56MP/E —
  $0.85$2.23
• LTRN

  Lantern Pharma Inc. Common Stock

  $2.08

  ▼ 3.70%
  Market cap $35.47MP/E —
  $1.11$4.7
• RADX

  Radiopharm Theranostics Limited American Depositary Shares

  $2.41

  ▲ 6.64%
  Market cap $40.11MP/E —
  $0.009$0.04
• HYPD

  Hyperion DeFi Inc. Common Stock

  $3.25

  ▼ 10.36%
  Market cap $40.47MP/E —
  $2.34$15

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target
  Benzinga · 8/12/2026
• Canaccord Genuity Maintains Buy on CervoMed, Lowers Price Target to $18
  Benzinga · 8/10/2026
• CervoMed Q2 EPS $(0.64) Misses $(0.60) Estimate
  Benzinga · 8/10/2026

• BOGER JOSHUA S · June 11, 2026 · Buy

  955.4K @ $3.14
• ZAVRL FRANK · June 8, 2026 · Grant

  8.2K
• Sabbagh Marwan · June 8, 2026 · Grant

  8.2K
• Quigley David · June 8, 2026 · Grant

  8.2K
• Poulton Jeffrey V. · June 8, 2026 · Grant

  8.2K
• Hollingsworth Jane H · June 8, 2026 · Grant

  8.2K
• Gregoire Sylvie · June 8, 2026 · Grant

  8.2K
• BOGER JOSHUA S · June 8, 2026 · Grant

  8.2K
• ALAM JOHN J · June 8, 2026 · Grant

  8.2K

Institutional Ownership

March 31, 2026

Total shares held

1.73M

Total value held

$6.82M

Institutional holders

34